Invest, Acquire, Partner, Collaborate
November 12-13, Boston MA
Advance clinical efficacy and commercial success of targeted cell depletion and immune tolerance technologies for Autoimmune Disease
CONFIRMED TO ATTEND
Why Autoimmunity Partnering Summit?
More Targeted
Uniting C-level and Business Development with aligned strategic and scientific interests across tolerance and targeted cell depletion, to increase interactions with a volume of viable partners.
Earlier Opportunity
People work with people, and with partnerships often delayed by not finding and building a relationship with the right individual sooner, meet the right contacts from buyers scouting earlier pipeline opportunities, sooner.
With Scientific Insights
Evaluate competitive landscapes, assess where your research fits within the broader landscape to differentiate, and meet with synergistic researchers to share risks through collaboration with complementary projects.
Size of the Networking Opportunity
Total Audience Networking
Creating Alignment Through Targeted Critical Mass: With a shared focus on scientific interests and partnering goals, attendees enjoy more meaningful interactions, free from distractions. This leads to higher-quality conversations, better engagement, and significantly improved follow-up opportunities
Individual Meetings: One-on-One Partnering™
Partnering Portal: Using the same partnering portal as BIO, search attendees and pre-schedule meetings into calendars ahead of the conference, with meeting automatically linked to a private meeting space.
Why Now?
The unprecedented clinical efficacy and investment generated by Candid Therapeutics' $370M debut has positioned TCE antibodies in the race with cell therapies, as targeted B cell depletion takes on the clinical efficacy and commercial success of Humira.
Combined with immune tolerization to rebuild a less aberrant immune system through engineered Tregs and antigen-specific immune tolerance; immune reset and reconstitution will change treatment paradigms dramatically.
But, despite this dynamic macroenvironment, the average biotech-pharma collaboration takes over a year, and with pharma receiving >700 invitations to connect at large conferences; not meeting the right contact in person is elongating biotech deal-making.
The Autoimmunity Pharma & Biotech Partnering Summit is the only event of its kind, laying enabled partnering on top of hyper-relevant scientific discussion so that pharma can contextualize and compare, and biotech can have guaranteed face-to-face meetings with key contacts specific to immunology deal-making.
EXPERT SPEAKERS INCLUDE
Chris Gagliardi
Principal
Sanofi Ventures
Nicola La Monica
Senior Director, Strategic Search & Evaluation
Johnson & Johnson
Swarna Balasubramanian
Associate Director, Search & Evaluation Respiratory & Immunology
AstraZeneca
Melissa Matzelle
Director, Immunology Search & Evaluation
AbbVie
Emma Smith
Head of Immune Reset
UCB
Testimonials
“This was a brilliant opportunity to connect with potential partners and hear meaningful talks and discussions relevant to the space."
“The event assembled a diverse set of stakeholders extremely relevant in ADC & RLT partnering, including pharma BD, investors, and biotech executives. It was the right size (~100 attendees) that created organic opportunities for connections”
OTHER HANSON WADE SUMMITS
